Avidicure
Oegstgeest
About Avidicure
Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.“AVC-Boosters”, designed to safely deliver targeted and potent monotherapy, with broad applicability in oncology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $50.0M
- Funding stage: Seed
- Last round: Seed (Apr 2025)
- Website: avidicure.com
Social Profiles
Canonical: https://fsome.com/organization/avidicure-68590 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.